Kepler Capital Markets set a €115.00 ($135.29) price objective on Merck KGaA (FRA:MRK) in a research note published on Monday, November 6th. The brokerage currently has a buy rating on the healthcare company’s stock.
MRK has been the topic of several other reports. J P Morgan Chase & Co set a €100.00 ($117.65) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Friday, October 6th. Citigroup Inc. set a €123.00 ($144.71) price objective on shares of Merck KGaA and gave the company a buy rating in a report on Monday, September 25th. Goldman Sachs Group Inc set a €105.00 ($123.53) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Tuesday, September 19th. DZ Bank AG reissued a sell rating on shares of Merck KGaA in a report on Tuesday, July 18th. Finally, UBS AG set a €120.00 ($141.18) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Monday, October 2nd. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of €108.76 ($127.96).
Shares of Merck KGaA (MRK) traded down €0.65 ($0.76) during midday trading on Monday, reaching €89.15 ($104.88). 541,451 shares of the company’s stock traded hands. Merck KGaA has a twelve month low of €88.73 ($104.39) and a twelve month high of €115.00 ($135.29).
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with our FREE daily email newsletter.